Polyamidoamine conjugates containing curcumin and bisphosphonate were synthesized via a one-pot aqueous phase Michael addition reaction. In the design of the conjugate, bisphosphonate formed an integral part of the polymer carrier backbone. Curcumin was incorporated onto the polyamidoamine backbone via piperazine linker. The conjugates were characterized by Fourier transform spectroscopy, energy-dispersive X-ray analysis, atomic force spectroscopy and nuclear magnetic resonance spectroscopy and it confirmed the successful incorporation of the antiproliferative agents onto the carriers. The weight percentage incorporation of bisphosphonate to the carriers was found to be between 2.56% and 3.34%. The in vitro release studies of curcumin from the polyamidoamine conjugate were performed in dialysis bag at selected pH values. The release of curcumin was significantly slower at pH 7.4 when compared to pH 5.8. The release profiles indicate that the conjugates are more stable at pH 7.4 and are potential sustained drug-delivery systems for combination therapy.
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Growth suppressing effect of extracts on cancerous cell line.
Cytotechnology
February 2025
Department of Microbiology, Dr. Ikram-Ul-Haq Institute of Industrial Biotechnology (IIIB), Government College University, Lahore, 54000 Pakistan.
Homeostasis of tissues requires a complex balance between cell proliferation and cell death. The disruption of this balance leads to tumors. Cancer is a mortal disease that spreads all over the body, it is an irregular cell growth.
View Article and Find Full Text PDFThe novel CD16A/anti-CD3 bifunctional protein, eCD16A/anti-CD3-BFP, redirects T cell cytotoxicity toward antibody-bound target cells.
Hum Vaccin Immunother
December 2025
Department of Research and Development, ManySmart Therapeutics, Taipei, Taiwan.
Monoclonal antibodies enhance innate immunity, while bispecific T cell engager antibodies redirect adaptive T cell immunity. To stimulate both innate and adaptive mechanisms, we created a bifunctional eCD16A/anti-CD3-BFP adapter protein for combined use with clinically approved monoclonal IgG1 antibodies. The adaptor protein contains the extracellular domain of the human CD16A high-affinity variant, which binds the Fc domain of IgG1 antibodies, and an anti-human CD3 single-chain variable fragment that redirects T cell cytotoxicity.
View Article and Find Full Text PDFEfficacy and Safety Analysis of Axitinib Combined with Sintilimab as Second-Line Treatment for Advanced Renal Cell Carcinoma: A Retrospective Study.
Arch Esp Urol
December 2024
Department of Emergency Surgery, Qingdao Eighth People's Hospital, 266000 Qingdao, Shandong, China.
Background: Targeted therapies, including axitinib, a vascular endothelial growth factor receptor inhibitor, and sintilimab, a programmed cell death protein-1 inhibitor, have shown promise in the treatment of advanced renal cell carcinoma (RCC). Although their individual efficacies have been demonstrated, the potential synergistic effects of combining these two agents are still being explored.
Methods: This study retrospectively analysed patients with advanced RCC admitted to our hospital from January 2022 to December 2023.
Compliance with Targeted Therapy and Fear of Adverse Drug Reactions in Patients with Renal Cell Carcinoma: A Nurse-Led Retrospective Descriptive Study.
Arch Esp Urol
December 2024
Department of Nephropathy, The First Affiliated Hospital of Harbin Medical University, 150000 Harbin, Heilongjiang, China.
Background: This study aimed to explore factors affecting adherence to targeted therapy in patients with renal cell carcinoma, focusing on the fear of adverse drug reactions.
Methods: This retrospective case-control study selected patients with renal cancer who received targeted therapy at our hospital from June 2021 to April 2023, categorising them based on their adherence to oral targeted drugs.
Results: Patients with good compliance reported significantly lower levels of fear related to disease progression and adverse drug reactions ( < 0.
The Role and Mechanism of Perilla Alcohol in Counteracting Doxorubicin-Induced Nephrotic Syndrome.
Arch Esp Urol
December 2024
Pediatric Surgery, Qilu Hospital of Shandong University, 250012 Jinan, Shandong, China.
Background: Doxorubicin (DOX) is a widely used anticancer drug; However, its nephrotoxicity limits its therapeutic efficacy. This study investigates the protective effects of Perilla Alcohol (PA) against DOX-induced nephrotic syndrome (NS), focusing on its antioxidant and anti-inflammatory properties through the nuclear factor erythroid 2-related factor 2 (Nrf2) and nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) pathways.
Methods: A DOX-induced nephrotic syndrome (NS) rat model and a DOX-treated Mouse Podocyte Cell line 5 (MPC5) cell model were used to evaluate the renal protective effects of PA.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!